治疗方式是否影响妊娠期糖尿病女性的动脉僵硬度指标
这项前瞻性纵向队列研究比较了155例低危对照与127例妊娠期糖尿病(GDM)孕妇的动脉僵硬度,GDM按饮食、二甲双胍单用、二甲双胍+胰岛素分层。结果显示GDM组在孕24+0至35+6周的肱动脉及主动脉增强指数显著高于对照,但主动脉脉搏波速度无组间差异,且各治疗方式间增强指数差异无统计学意义。
要点
- GDM孕妇在孕24+0至35+6周肱动脉及主动脉增强指数显著高于低危对照。
- AoPWV在各研究组间无显著差异(P=0.729)。
- 各GDM治疗方式间BrAIx与AoAIx差异在任何孕周窗口均无统计学意义。
核心结论
- GDM妊娠无论采用何种治疗方式,其动脉僵硬度均显著高于低危妊娠;数据为进一步研究二甲双胍治疗与动脉僵硬度变化及胎盘介导疾病风险的关联提供了基础。
研究设计与样本
- 前瞻性纵向队列研究,纳入155例低危对照和127例GDM孕妇(饮食干预59例、单用二甲双胍47例、二甲双胍+胰岛素21例),使用Arteriograph®在四个孕周窗口(W1:24+0至27+6周;W2:28+0至31+6周;W3:32+0至35+6周;W4:≥36+0周)测量AoPWV、BrAIx和AoAIx。
诊断标准与关键数值
- 采用线性混合模型分析各动脉僵硬度变量(对数转换),固定效应包括组别、孕周窗口、母亲年龄、种族、产次、体重指数、平均动脉压和心率,个体作为随机效应,组间均值比较采用Bonferroni校正。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate whether arterial stiffness (AS) differs between healthy women and women with gestational diabetes mellitus (GDM) managed by different treatment modalities.
METHODS: This was a prospective longitudinal cohort study comparing AS in pregnancies complicated by GDM and low-risk controls. AS was assessed by recording aortic pulse-wave velocity (AoPWV), brachial augmentation index (BrAIx) and aortic augmentation index (AoAIx) using the Arteriograph® at four gestational-age windows: 24 + 0 to 27 + 6 weeks (W1); 28 + 0 to 31 + 6 weeks (W2); 32 + 0 to 35 + 6 weeks (W3) and ≥ 36 + 0 weeks (W4). Women with GDM were considered both as a single group and as subgroups stratified by treatment modality. Data were analyzed using a linear mixed model on each AS variable (log-transformed) with group, gestational-age window, maternal age, ethnicity, parity, body mass index, mean arterial pressure and heart rate as fixed effects and individual as a random effect. We compared the group means including relevant contrasts and adjusted the P-values using Bonferroni correction.
RESULTS: The study population comprised 155 low-risk controls and 127 women with GDM, of whom 59 were treated with dietary intervention, 47 were treated with metformin only and 21 were treated with metformin + insulin. The two-way interaction term of study group and gestational age was significant for BrAIx and AoAIx (P < 0.001), but there was no evidence that mean AoPWV was different between the study groups (P = 0.729). Women in the control group demonstrated significantly lower BrAIx and AoAIx compared with the combined GDM group at W1-W3, but not at W4. The mean difference in log-transformed BrAIx was -0.37 (95% CI, -0.52 to -0.22), -0.23 (95% CI, -0.35 to -0.12) and -0.29 (95% CI, -0.40 to -0.18) at W1, W2 and W3, respectively. The mean difference in log-transformed AoAIx was -0.49 (95% CI, -0.69 to -0.30), -0.32 (95% CI, -0.47 to -0.18) and -0.38 (95% CI -0.52 to -0.24) at W1, W2 and W3, respectively. Similarly, women in the control group also demonstrated significantly lower BrAIx and AoAIx compared with each of the GDM treatment subgroups (diet, metformin only and metformin + insulin) at W1-W3. The increase in mean BrAIx and AoAIx seen between W2 and W3 in women with GDM treated with dietary management was attenuated in the metformin-only and metformin + insulin groups. However, the mean differences in BrAIx and AoAIx between these treatment groups were not statistically significant at any gestational-age window.
CONCLUSIONS: Pregnancies complicated by GDM demonstrate significantly higher AS compared with low-risk pregnancies regardless of treatment modality. Our data provide the basis for further investigation into the association of metformin therapy with changes in AS and risk of placenta-mediated diseases. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Anness AR, Nath M, Osman MW, et al. Does treatment modality affect measures of arterial stiffness in women with gestational diabetes? Ultrasound Obstet Gynecol. 2023. PMID: 37099764. doi:10.1002/uog.26234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。